Citations

Showing 10 of 108152 citations.

Massive Pulmonary Embolism Causing Cardiac Arrest Managed with Systemic Thrombolytic Therapy: A Case Report
Welle, Stephanie, Harrison, Michael F. , Welle, Stephanie R

Mayo Clinic

American Journal of Case Reports | June 7, 2021 | Volume: 22 | Issue: No issue available | Pages: No page available

10.12659/ajcr.931215 | PMID 34228699 Get It

MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Yang, Qifan, Zeng, Xiangyu , Wang, Manxiang , Tu, Xinyi , Wei, Ting , Xie, Wenzhuan , Guo, Qiang , Kloeber, Jake A. , Cao, Yueyu, Guo, Guijie , Zhou, Qin , Huang, Jinzhou , Zhang, Kai , Luo, Kuntian, Kim, Wootae , Hou, Jing , Shi, Yu , Zhu, Qian , Hu, Sheng , Yue, Junqiu , Pi, Guoliang , Kloeber, Jake A , Liu, Li , Kim, Wootae , Zhu, Qian , Wei, Ting , Zeng, Xiangyu , Zhang, Yong , Dong, Shuang , Yang, Bin , Zhang, Chao , Zhao, Fei Linda , Liu, Li , Wang, Mingwei , Yin, Ping , Deng, Min , Chen, Lifeng , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Cancer Discovery | June 7, 2021 | Volume: 11 | Issue: 11 | Pages: 2726-2737

10.1158/2159-8290.cd-20-1500 | PMID 34099454 Get It

Abstract Immune checkpoint blockade (ICB) has revolutionized cancer therapy. However, the response of patients to ICB is difficult to predict. Here, we examined 81 patients with lung cancer under ICB treatment and found that patients with MET amplification were resistant to ICB and had a poor progression-free survival. Tumors with MET amplifications had significantly decreased STING levels and antitumor T-cell infiltration. Furthermore, we performed deep single-cell RNA sequencing on more than 20,000 single immune cells and identified an immunosuppressive signature with increased subsets of XIST- and CD96-positive exhausted natural killer (NK) cells and decreased CD8+ T-cell and NK-cell populations in patients with MET amplification. Mechanistically, we found that oncogenic MET signaling induces phosphorylation of UPF1 and downregulates tumor cell STING expression via modulation of the 3′-UTR length of STING by UPF1. Decreased efficiency of ICB by MET amplification can be overcome by inhibiting MET. Significance: We suggest that the combination of MET inhibitor together with ICB will overcome ICB resistance induced by MET amplification. Our report reveals much-needed information that will benefit the treatment of patients with primary MET amplification or EGFR–tyrosine kinase inhibitor resistant-related MET amplification. This article is highlighted in the In This Issue feature, p. 2659
Correlation of Intravascular Ultrasound and Instantaneous Wave-Free Ratio in Patients With Intermediate Left Main Coronary Artery Disease
Hajj, Stephanie C. El , Toya, Takumi , Warisawa, Takayuki , Nan, John , Lewis, Bradley R., Cook, Christopher , Rajkumar, Christopher , Howard, James P. , Seligman, Henry , Ahmad, Yousif , Doi, Shunichi , Nakajima, Akihiro , Nakayama, Masafumi , Goto, Sonoka, Vera-Urquiza, Rafael , Sato, Takao , Kikuta, Yuetsu , Kawase, Yoshiaki , Nishina, Hidetaka , Nakamura, Sunao , Matsuo, Hitoshi , Escaned, Javier , Akashi, Yoshihiro J. , El Hajj, Stephanie C, Toya, Takumi , Cook, Christopher M , Akashi, Yoshihiro J , Escaned, Javier , Hajj, Stephanie C. El , Doi, Shunichi, Davies, Justin E. , Lerman, Amir

Mayo Clinic

Circulation: Cardiovascular Interventions | June 7, 2021 | Volume: 14 | Issue: 6 | Pages: No page available

10.1161/circinterventions.120.009830 | PMID 34092096 Get It

Background: There is great degree of interobserver variability in the visual angiographic assessment of left main coronary disease (LMCD). Fractional flow reserve and intravascular ultrasound are often used in this setting. The use of instantaneous wave-free ratio (iFR) for evaluation of LMCD has not been well studied. The aim of this study is to evaluate the use of iFR in the assessment of angiographically intermediate LMCD. Methods: This is an international multicenter retrospective observational study of patients who underwent both iFR and intravascular ultrasound evaluation for angiographically intermediate LMCD. An independent core laboratory performed blinded off-line analysis of all intravascular ultrasound data. A minimum lumen area of 6 mm 2 was used as the cutoff for significant disease. Results: One hundred twenty-five patients (mean age, 68.4±9.5 years, 84.8% male) were included in this analysis. Receiver operating curve analysis showed that an iFR of ≤0.89 identified minimum lumen area <6 mm 2 with an area under the curve of 0.77 (77% sensitivity, 66% specificity; P <0.0001). Among the 69 patients without ostial left anterior descending artery or left circumflex artery disease, receiver operating curve analysis showed that an iFR of ≤0.89 identified minimum lumen area <6 mm 2 with an area under the curve of 0.84 (70% sensitivity, 84% specificity; P <0.0001). The correlation was not significantly different when the body surface area was considered. Conclusions: In this study, in patients with intermediate LMCD, iFR of ≤0.89 correlates with intravascular ultrasound minimum lumen area <6 mm 2 regardless of body surface area. The current study supports the use of iFR for the evaluation of intermediate LMCD.
The Association between Pulse Pressure and Stroke Volume during Lower Body Negative Pressure and Graded Hemorrhage
Helmond, Noud van , Johnson, Blair D. , Curry, Timothy B. , Convertino, Víctor A. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 7, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.1206.4 Get It

Due to the relationship between stroke volume (SV) and pulse pressure (PP) during lower body negative pressure (LBNP), we hypothesized that PP reflects SV during hemorrhage (HEM). After a 5‐minute baseline, 6 men were exposed to LBNP at ‐15, ‐30, and ‐45 mmHg for 5 minutes at each pressure. After 45 minutes of recovery, three progressive 333‐ml stages of HEM (1 L total) were performed. SV was assessed using a CC Nexfin and PP was calculated using an arterial catheter. SV (111 ± 2.1 vs. 77 ± 6.7 mL; p = 0.04) and PP (58±2.7 vs. 41 ± 4.3 mm Hg; p = 0.03) decreased from baseline to ‐45 mmHg LBNP. SV (118 ± 4.4 to 99 ± 6.8 mL; p = 0.06) and PP decreased (58 ± 2.9 to 48 ± 4.9 mmHg; p = 0.06) from baseline to ‐1 L of HEM. PP correlated with SV during HEM (amalgamated r 2 = 0.98) and LBNP (amalgamated r 2 = 0.99). There was limited inter‐subject variability in PP vs. SV during LBNP ( r 2 range 0.57 to 0.99, 5/6 had an r 2 >; 0.90), but substantial inter‐subject variability during HEM ( r 2 range 0.21 to 0.99, 2/6 had an r 2 >; 0.90). Reductions in PP induced by LBNP or HEM are strongly correlated with SV. However large inter‐individual differences in this correlation during HEM, which may indicate a significantly variable compensatory response in human arterial distensibility, may limit the use of PP as a surrogate for SV during clinical blood loss. Funded by U.S. Army MRMC Combat Casualty Care Research Program Grant # W81XWH‐11–1‐0823.
Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol‐Associated Hepatitis
Zhang, Ting , Kusumanchi, Praveen , Tang, Qing , Sun, Zhaoli , Radaeva, Svetlana , Peiffer, Brandon , Shah, Vijay H. , Kamath, Patrick S. , Gores, G. J., Chalasani, Naga , Jiang, Yanchao, Ma, Jing , Liangpunsakul, Suthat , Shah, Vijay H , Kamath, Patrick, Gores, Greg J, Chalasani, Naga , Peiffer, Brandon , Yang, Zhihong , Sanyal, Arun J. , Huda, Nazmul

Mayo Clinic

Hepatology | June 7, 2021 | Volume: 74 | Issue: 5 | Pages: 2436-2451

10.1002/hep.31994 | PMID 34096637 Get It

Background and Aims We conducted a comprehensive serum transcriptomic analysis to explore the roles of microRNAs (miRNAs) in alcohol‐associated hepatitis (AH) pathogenesis and their prognostic significance. Approach and Results Serum miRNA profiling was performed in 15 controls, 20 heavy drinkers without liver disease, and 65 patients with AH and compared to publicly available hepatic miRNA profiling in AH patients. Among the top 26 miRNAs, expression of miR‐30b‐5p, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p were significantly reduced in both serum and liver of AH patients. Pathway analysis of the potential targets of these miRNAs uncovered the genes related to DNA synthesis and cell‐cycle progression pathways, including ribonucleotide reductase regulatory subunit M2 (RRM2), cyclin D1 (CCND1), cyclin D2 (CCND2), MYC proto‐oncogene (MYC), and phorbol‐12‐myristate‐13‐acetate‐induced protein 1 (PMAIP1). We found a significant increase in the protein expression of RRM2, CCND1, and CCND2, but not MYC and PMAIP1, in AH patients who underwent liver transplantation; miR‐26b‐5p and miR‐30b‐5p inhibited the 3′‐UTR (untranslated region) luciferase activity of RRM2 and CCND2, and miR‐20a‐5p reduced the 3′‐UTR luciferase activity of CCND1 and CCND2. During a median follow‐up of 346 days, 21% of AH patients died; these patients had higher body mass index (BMI), Model for End‐Stage Liver Disease (MELD), and serum miR‐30b‐5p, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p than those who survived. Cox regression analysis showed that BMI, MELD score, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p predicted mortality. Conclusions Patients with AH attempt to deal with hepatocyte injury by down‐regulating specific miRNAs and up‐regulating genes responsible for DNA synthesis and cell‐cycle progression. Higher expression of these miRNAs, suggestive of a diminished capacity in liver regeneration, predicts short‐term mortality in AH patients.
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
Sculier, Claudine , Aguilar, Cristina Barcia , Gaspard, Nicolas , Gaínza‐Lein, Marina , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Burrows, Brian T., Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Gorman, Mark , McDonough, Tiffani L. , Mikati, Mohamad A. , Nayak, Anuranjita , Peariso, Katrina , Riviello, James J. , Rusie, Allison, Sperberg, Katherine , Stredny, Coral M. , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, pSERG, Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Lai, Yi-Chen , Mikati, Mohamad A , Arya, Ravindra , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaspard, Nicolas , Gaillard, William D , Glauser, Tracy A. , Lai, Yi‐Chen , Tchapyjnikov, Dmitry , Loddenkemper, Tobias , pSERG

Mayo Clinic

Epilepsia | June 7, 2021 | Volume: 62 | Issue: 7 | Pages: 1629-1642

10.1111/epi.16950 | PMID 34091885 Get It

AbstractObjectiveWe aimed to characterize the clinical profile and outcomes of new onset refractory status epilepticus (NORSE) in children, and investigated the relationship between fever onset and status epilepticus (SE).MethodsPatients with refractory SE (RSE) between June 1, 2011 and October 1, 2016 were prospectively enrolled in the pSERG (Pediatric Status Epilepticus Research Group) cohort. Cases meeting the definition of NORSE were classified as "NORSE of known etiology" or "NORSE of unknown etiology." Subgroup analysis of NORSE of unknown etiology was completed based on the presence and time of fever occurrence relative to RSE onset: fever at onset (≤24 h), previous fever (2 weeks–24 h), and without fever.ResultsOf 279 patients with RSE, 46 patients met the criteria for NORSE. The median age was 2.4 years, and 25 (54%) were female. Forty (87%) patients had NORSE of unknown etiology. Nineteen (48%) presented with fever at SE onset, 16 (40%) had a previous fever, and five (12%) had no fever. The patients with preceding fever had more prolonged SE and worse outcomes, and 25% recovered baseline neurological function. The patients with fever at onset were younger and had shorter SE episodes, and 89% recovered baseline function.SignificanceAmong pediatric patients with RSE, 16% met diagnostic criteria for NORSE, including the subcategory of febrile infection‐related epilepsy syndrome (FIRES). Pediatric NORSE cases may also overlap with refractory febrile SE (FSE). FIRES occurs more frequently in older children, the course is usually prolonged, and outcomes are worse, as compared to refractory FSE. Fever occurring more than 24 h before the onset of seizures differentiates a subgroup of NORSE patients with distinctive clinical characteristics and worse outcomes.
Structural Elucidation of Engineered Tissue Inhibitor of Metalloproteinases‐1 (TIMP‐1) Variants with Improved Binding Affinity toward Matrix Metalloproteinase‐3 (MMP‐3)
Raeeszadeh‐Sarmazdeh, Maryam , Sankaran, Banumathi , Radisky, Derek C. , Radisky, Evette S.

Mayo Clinic

The FASEB Journal | June 7, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.467.2 Get It

Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of matrix metalloproteinases (MMPs), enzymes known for contributions to diseases including cancer and fibrosis. The TIMP N‐terminal domain, regarded as the “inhibitory domain”, has been the center of attention both for understanding natural regulation of MMPs by TIMPs, and for developing protein‐based MMP inhibitors for therapeutic applications. The role of the TIMP C‐terminal domain in MMP inhibition has not been well studied. I have used directed evolution via yeast surface display for protein engineering of full‐length human TIMP‐1 toward development of MMP‐3‐targeted ultra‐binders. TIMP‐1 variants with up to 10‐fold improvement in MMP‐3 binding (compared to WT‐TIMP‐1) were isolated after six rounds of library screening using fluorescence‐activated cell sorting (FACS). Analysis of individual and paired mutations from the selected TIMP‐1 variants revealed a cooperative effect between distant mutations on the N‐ and C‐terminal TIMP domains, positioned on opposite sides of the interaction interface with MMP‐3. I have co‐crystallized two TIMP‐1 variants containing single and composite mutations in complex with the catalytic domain of MMP‐3 and solved the X‐ray crystal structures of these complexes. The protein structures reveal substantial conformational changes in the TIMP‐1 binding interfaces near the two cooperative mutations. Affinity appears to be strengthened by tighter cinching of a reciprocal tyrosine clasp formed between the N‐terminal loop of TIMP‐1 and the proximal MMP3 interface, and adoption of an alpha‐helical conformation by a segment of the TIMP‐1 C‐terminal domain, resulting in stabilized interactions between the two TIMP‐1 domains and improved hydrophobic interactions between TIMP‐1 and MMP‐3. Our protein engineering and structural studies provide novel insight into the cooperative function of N‐ and C‐terminal TIMP domains and the significance of peripheral TIMP epitopes in MMP recognition. Our results further point to new approaches for design of TIMP‐based protein therapeutics with improved affinity and selectivity. Support or Funding Information This work was supported by grants DOD W81XWH‐16‐2‐0030, and NIH R21 CA205471. Diffraction data were measured at the Berkeley National Synchrotron Light Source. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Hemodynamic responses to simulated hemorrhage: Role for the carotid bodies
Holbein, Walter W., Johnson, Blair D. , Convertino, Víctor A. , Curry, Timothy B. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 7, 2021 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1241.4 Get It

Background Lower body negative pressure (LBNP) increases carotid body chemosensitivity. Whether the increase in chemosensitivity is functionally significant in the hemodynamic response to LBNP was previously unknown. We tested the hypothesis that desensitization of the carotid body chemoreceptors would improve the hemodynamic response to LBNP. Methods Ten healthy, non‐obese male subjects (35 ± 3 years, BMI: 25 ± 1 kg/m 2 ) completed 2 study visits (Saline, Dopamine), separated by a minimum of 4 weeks. Intravenous dopamine was infused at an individualized dose (1–2 mg/kg/min) shown to maximally blunt the hypoxic ventilatory response (a measure of carotid body chemosensitivity). Arterial blood pressure (brachial catheter) and heart rate (ECG) were continuously recorded. On each study day subjects underwent step‐wise exposures of LBNP (−15, −30, and −45 mmHg) to simulate hemorrhage. Cumulative stress index (CSI) was calculated by summating the product of negative pressure (mmHg) by the time (min) during each LBNP level (−15, −30, and −45 mmHg). Results Dopamine tended to reduce CSI (Saline: 503 ± 52; Dopamine: 408 ± 45 mmHg*min; p=0.07). Changes in heart rate from baseline during graded LBNP were not statistically distinguishable between Saline and Dopamine conditions (− 15 mmHg: +4 ± 1 vs +3 ± 2 BPM, p=0.99; − 30 mmHg: +12 ± 1 vs +12 ± 3 BPM, p=0.99; − 45 mmHg: HR +21 ± 2 vs +19 ± 5 BPM, p=0.99). Similarly, change in systolic blood pressure from baseline during graded LBNP was not different between Saline and Dopamine conditions (− 15 mmHg: +1 ± 1 vs −1 ± 2 mmHg p=0.99; − 30 mmHg: −7 ± 3 vs −6 ± 4 mmHg, p=0.99; − 45 mmHg: −12 ± 4 vs −22 ± 6 mmHg, p=0.19). However, change in diastolic blood pressure from baseline during graded LBNP was higher at −45 mmHg between Saline and Dopamine conditions (− 15 mmHg: +2 ± 1 vs −0 ± 1 mmHg p=0.47; − 30 mmHg: −1 ± 2 vs −2 ± 2 mmHg p=0.26; − 45 mmHg: −2 ± 2 vs −12 ±3 mmHg, p=0.0004). Conclusions Desensitization of the carotid body chemoreceptors reduced diastolic blood pressure responses to LBNP at −45 mmHg only, with minimal effect at lower levels. These data suggest chemoreflex activity during LBNP may be functionally significant in the blood pressure responses only during higher levels of simulated hemorrhage. Support or Funding Information Funding: W81XWH‐13‐2‐0038 (DOD)
White Blood Cell Counts during Lower Body Negative Pressure vs. Blood Loss in Humans
Cap, Andrew P, Helmond, Noud van , Johnson, Blair D. , Curry, Timothy B. , Cap, Andrew P, Convertino, Víctor A. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 7, 2021 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1241.1 Get It

Hypovolemia‐induced sympathoexcitation might initiate an immune response through an increase in circulating epinephrine and splenic demargination. We tested the hypothesis that lower body negative pressure (LBNP) and blood loss (BL) result in comparable increases in white blood cell counts (WBCs). We determined WBCs and epinephrine levels in 12 men who performed a LBNP and BL protocol in a randomized order. LBNP consisted of 5‐minute stages at 0, ‐15, ‐30, and ‐45 mmHg of suction. BL included 5 minutes at baseline and following three stages of 333 mL of blood removal (up to 1000 mL total). Blood draws were performed at baseline and after the last stage of each protocol. LBNP to −45mmHg was a greater central hypovolemic stimulus vs. BL, therefore WBCs and epinephrine concentrations were plotted against central venous pressure (CVP) to obtain stimulus‐response relationships using the linear regression line slopes for both protocols. Paired tests were used to determine if the slopes of these regression lines fell on similar trajectories for each protocol. Mean regression line slopes fell on similar trajectories for total WBC (LBNP 183±46 vs. BL 155±109 mcL −1 *mmHg −1 , p=0.15), neutrophils (LBNP 110±29 vs. BL 96±72 mcL −1 *mmHg −1 , p=0.15) and lymphocytes (LBNP 65±21 vs. BL 59±38 mcL −1 *mmHg −1 , p=0.90). Mean regression line slopes for epinephrine were similar as well (LBNP 15±5 vs. BL 16±4 pg *mL −1 *mmHg −1 , p=0.84). Our results indicate that LBNP models the stimulus‐response relationship between CVP and WBCs observed during BL. Central hypovolemia, induced by LBNP or BL, elicits a relative leukocytosis with a predominantly neutrophil‐based response. Support or Funding Information US Army MRMC Combat Casualty Care Research Program Grant # W81XWH‐11‐1‐0823
Management of Chronic and Neuropathic Pain with 10 kHz Spinal Cord Stimulation Technology: Summary of Findings from Preclinical and Clinical Studies
Francio, Vinicius Tieppo , Polston, Keith F. , Murphy, Micheal T. , Hagedorn, Jonathan M. , Tieppo Francio, Vinicius , Hagedorn, Jonathan M , Sayed, Dawood

Mayo Clinic

Biomedicines | June 6, 2021 | Volume: 9 | Issue: 6 | Pages: 644

10.3390/biomedicines9060644 | PMID 34200097 Get It

Since the inception of spinal cord stimulation (SCS) in 1967, the technology has evolved dramatically with important advancements in waveforms and frequencies. One such advancement is Nevro’s Senza® SCS System for HF10, which received Food and Drug and Administration (FDA) approval in 2015. Low-frequency SCS works by activating large-diameter Aβ fibers in the lateral discriminatory pathway (pain location, intensity, quality) at the dorsal column (DC), creating paresthesia-based stimulation at lower-frequencies (30–120 Hz), high-amplitude (3.5–8.5 mA), and longer-duration/pulse-width (100–500 μs). In contrast, high-frequency 10 kHz SCS works with a proposed different mechanism of action that is paresthesia-free with programming at a frequency of 10,000 Hz, low amplitude (1–5 mA), and short-duration/pulse-width (30 μS). This stimulation pattern selectively activates inhibitory interneurons in the dorsal horn (DH) at low stimulation intensities, which do not activate the dorsal column fibers. This ostensibly leads to suppression of hyperexcitable wide dynamic range neurons (WDR), which are sensitized and hyperactive in chronic pain states. It has also been reported to act on the medial pathway (drives attention and pain perception), in addition to the lateral pathways. Other theories include a reversible depolarization blockade, desynchronization of neural signals, membrane integration, glial–neuronal interaction, and induced temporal summation. The body of clinical evidence regarding 10 kHz SCS treatment for chronic back pain and neuropathic pain continues to grow. There is high-quality evidence supporting its use in patients with persistent back and radicular pain, particularly after spinal surgery. High-frequency 10 kHz SCS studies have demonstrated robust statistically and clinically significant superiority in pain control, compared to paresthesia-based SCS, supported by level I clinical evidence. Yet, as the field continues to grow with the technological advancements of multiple waveforms and programming stimulation algorithms, we encourage further research to focus on the ability to modulate pain with precision and efficacy, as the field of neuromodulation continues to adapt to the modern healthcare era.